Abrysvo is indicated for: Passive protection against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age following maternal immunisation during pregnancy. See Dosage & Administration and Pharmacology: Pharmacodynamics under Actions.
Active immunisation of individuals 18 years of age and older for the prevention of lower respiratory tract disease caused by RSV.
Other Services
Country
Account